# DSciLab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dscilab

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: ww.dscilaboratory.com
- Total disclosed funding: $14M
- Latest round: Series A (Oct 23, 2025)
- Investors on record: 3

## About

Founded in 2022 and based in Suzhou, China, DSciLab is a biotech company that focuses on the development of mRNA drugs. Changyou Zhan, the company's CSO and founder, is also a distinguished professor of Fudan University and the head of the key innovation team of Shanghai "Gao Jian". In February 2023, the company completed the Shanghai R&D Lab. In October 2025, DSciLab raised a series A funding from new investor JenKem Technology Co., Ltd. and returning investor Fosun Health Capital.

DSciLab developed Intelligent Screening Platform for Delivery Systems to launch main products, library of lipid nano-delivery systems and liver-targeted delivery systems. The liver-targeted delivery system completes animal experimental verification and IIT clinical verification services for the development of mRNA drugs for rare liver diseases.

DSciLab generates revenue by providing construction of mRNA drug lipid nanodelivery system libraries and mRNA drug development services.

The company will focus on its clinical demand-driven drug development process.

## Funding rounds

- Series A, Oct 23, 2025 — JenKem Technology Co., Ltd., Fosun Health Capital
- Angel, Apr 30, 2024, $14M — Shanghai Creation Investment, Fosun Health Capital
- Seed, Jul 11, 2022 — Fosun Health Capital

## Investors

- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Seed, Angel, Series A
- Shanghai Creation Investment (https://capitalatlas.ai/funds/shanghai-creation-investment) — Angel
- JenKem Technology Co., Ltd. — Series A